Futura Medical Share Discussion Threads

[mdi] 16/4/2024 10:34

More information has been again taken down from the Futura website. As happened before and was previously written about ‘The vanishing FAQ’

The Erection of a Placebo
When yesterday's placebo is tomorrow's treatment

[petroc] 16/4/2024 09:56

I think he finishes his security shift at 8 in the morning, so he probably has. He must have forgotten to take his crayons last night because he didn't share his 'special' knowledge about Erexon/Eroxon, for a change!

[broomrigg] 16/4/2024 07:16

When do you reckon Glavey?

[glavey] 16/4/2024 04:35

Notable spend on plant & equipment last financial year - wonder what they bought.
Anyone have any ideas as to the timing of the next cash raise?

[mdi] 15/4/2024 23:37

Also according to Ceuta if ‘Online provided the majority of sales’ for Eroxon. Is that how Futura were able come up with the market share they touted in the RNS that Eroxon supposedly captured in the early days of launching in UK and Belgium of ‘c. 20% market share of approved ED treatments’. So Eroxon actually just captured 20% of a smalll online market of approved ED treatments ie mainly online sales of other medical devices which are also all ‘approved ED treatments. But which mostly excludes the online sale of drugs like Viagra, Cialis etc. As online sales are mostly an ’option not open to “pharmacy” (P) classified medicines like sildenafil and tadalafil, which can only be dispensed after consultation with a pharmacy professional’

[mdi] 15/4/2024 21:38

And yet another contradiction to what Futura told shareholders. The UK distributor Ceuta Healthcare, marketing director Jon Connolly said ‘Online provided the majority of sales’ ‘While physical sales were “kind of slow”. So again they could track the majority of online sales and give a repurchase rate.But maybe they didn’t want more detailed figures. As it already appears to be obvious from the declining revenues what is happening. Eroxon revenue was £1.7m in April/May and only £1.4m in the following 6 months

[petroc] 15/4/2024 20:32

MDI, it's impossible to underestimate you. There was a little too much chlorine in your gene pool. You don’t need to fear success, you have nothing to worry about.

[mdi] 15/4/2024 19:48

Here is another contradiction to what was claimed in the Futura presentation. About them not being unable to provide any details to shareholders on repeat purchasers?

‘If a someone wants to buy Eroxon on Amazon, their credit card details and delivery addresses are already there’

[mdi] 15/4/2024 16:42

Sounds like during the launch ‘hype cycle’ they got journalists to print headlines that ‘wouldn’t be allowed’ in advertising?



‘Thanks to help from marketing firm Jungle Cat Solutions, Ceuta was able to use PR effectively’

‘The PR was phenomenal,” Connolly commented. “Those headlines just had potency that you would never, ever be able to get in advertising because they just wouldn't be allowed’

Wellness Investors:

Beware The Placebo Trap

Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones

[petroc] 15/4/2024 16:19

I would explain it to you, MDI/LBO etc, but I don't have the time or the crayons.

[mdi] 15/4/2024 15:56

Don’t forget Futura apparently won an award for spending the best big budget on marketing Eroxon. And since Eroxon only launched in April 2023 they managed to spend the over £0.5 million required in marketing in an even shorter period. Just between April 2023 - August 2023. Again more evidence of the ‘hype cycle’. Also I dont understand why Futura win an award for what Cooper are supposed to be spending on marketing?



BEST BIG BUDGET OTC MARKETING CAMPAIGN

This Award is designed for big-budget OTC brands which have been supported by a total marketing spend – both above-the-line and below-the – line – exceeding £0.5 million between August 2022 – August 2023

WINNER

Eroxon, Futura Medical

[mdi] 15/4/2024 12:43

Sales of Eroxon apparently £1.7m in April/May, followed by £1.4m in the following 6 months? That revenue deceleration is telling there was a large ‘hype cycle’ that may have misled some men in new launch markets to buy and believe the ‘hype’ around a ‘clinically proven’ placebo hydroalcoholic gel. Especially a gel that was only tested on men who had to already report being able to respond to manual stimulation. But eventually they will run out of new markets to launch to prop up the declining revenue in markets they have launched and the hype is giving way to complaints about being misled?



Wellness Investors: Beware The Placebo Trap

Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones.

Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle.

[mdi] 15/4/2024 12:19

Others it seems too know of legal risks in the EU to Eroxon that could cause a ‘significant reversal in the amount of cumulative revenue’. Is this what the CEO was eluding too when he mentioned in the Q&A there had been complaints about Eroxon? Does not matter if the level of complaints per number of packs sold is low. Lawyers could argue that low level can actually be taken a reflection that the marketing was misleading most men. What matters is if any of the complainants have a genuine legal case. A case which then eventually becomes public and then many other customers who hadn’t originally complained say they too were misled all along and it becomes a massive class action?



The successful CE certification of a medical device or remedy does not release companies from the obligation to prove the correctness of advertising statements.

‘the CE conformity assessment is neither an official approval procedure nor an administrative legal act. The so-called “notified bodies” which carry out conformity checks and award the CE-certificates are private companies. The tests carried out by these companies therefore rather amount to plausibility checks, which, moreover, only concern individual aspects, for example, of a production process. A product’s (alleged) therapeutic effectiveness is not (necessarily) examined’



‘Companies on the Defensive as European Union Rolls Out Class-Action Lawsuits. Legal changes across the bloc could see companies hit with more pricey U.S.-style claims under consumer protection laws’

[mdi] 14/4/2024 17:57

Is it due to a legal risks that the distributors are not paying Futura? The distributors don’t have to pay until they decide its ‘probable that a significant reversal in the amount of cumulative revenue recognised will not occur’?




‘Other variable considerations such as milestone payments and royalties are not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. In managements opinion, that will be when the Groups customer confirms that the milestone has been met or that a royalty is due’




FTC settles false advertising suit against low-level light therapy marketer with $22 million judgment

Consumers may not be aware that, as the FDA explains, “Registration and Listing does not denote approval or clearance of a firm or their devices”, meaning that when you see “FDA registered” or “FDA listed” in advertising it not indicative of the efficacy or safety of the product, no matter how much the marketer would like you to believe otherwise.)



˜with MED3000 taking a ‘least burdensome approach’



This approach only requires a low class medical device to meet the threshold of ‘reasonable assurance’ of some effect including the effect just being a placebo effect.So Eroxon still has not been ‘clinically proven’ to have any effect beyond a similar placebo hydroalcoholic gel in any fully blinded study. A standard that all PDE5i drugs meet.



Devices are subject to weaker standards than drugs because they are regulated under a different law. The Medical Device Amendments of 1976 was intended to encourage innovation while allowing for a range of review standards based on risk, according to legal expert Richard A. Merrill. An array of corporate lobbying has since prompted Congress to ease regulations and make it easier for devices to get the FDA OK

We really dont know what we are getting with many of these devices

Ninety-nine percent of devices never have to provide clinical data, thanks in part to the 2002 Medical Devices User Fee Act, which requires the FDA to use the least burdensome route

For the few devices subject to a scientific review, the quality standards are flimsy. Randomized controlled trials, the gold standard, are infrequent. Most studies are unblinded, and thus prone to bias. The FDA settles for loosely defined reasonable assurance that a device is safe and effective, versus its higher standard of substantial evidence for drugs, which require studies with comparison groups that didnt receive the same treatment. Thus, data that would never be sufficient to support the approval of a drug can result in the approval of a device used to treat the same condition, potentially diverting patients from effective drugs to less-effective devices.